Communication Insurance Coverage and Processing Magazine 
Pharmaceutical Technology
JUNE 6, 2025
The approval process for cell and gene therapy candidates is tricky, however, given their high-cost and oft-debated benefit-risk ratio. RFK Jr did not question their importance, and acknowledged panellists’ calls for faster regulatory processes. Cell & Gene Therapy coverage on Pharmaceutical Technology is supported by Cytiva.
pharmaphorum
NOVEMBER 1, 2022
When Plaid effectively forced financial institutions to take an open-protocol approach to digital interoperability, “Every bank (took) their five-year strategy on digitizing and brought it down into one or two years,” CEO Zach Perret said in an interview with Fortune magazine. The patient’s journey is typically long and complicated ?
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Pharmaceutical Technology
JUNE 12, 2025
Cell & Gene Therapy coverage on Pharmaceutical Technology is supported by Cytiva. We may still continue to send you service-related and other non-promotional communications. Editorial content is independently produced and follows the highest standards of journalistic integrity. Sign up for our daily news round-up!
Pharmaceutical Technology
JUNE 16, 2025
These platforms are designed for safe drug production while allowing scaleable manufacturing processes. mRNA vaccine coverage on Pharmaceutical Technology (or Clinical Trials Arena) is supported by Trilink. The trial data indicated dose-dependent protein production at the site without systemic bioavailability. “By
Pharmaceutical Technology
JUNE 16, 2025
Cell & Gene Therapy coverage on Pharmaceutical Technology is supported by Cytiva. We may still continue to send you service-related and other non-promotional communications. Editorial content is independently produced and follows the highest standards of journalistic integrity. Sign up for our daily news round-up!
Pharmaceutical Technology
JUNE 13, 2025
mRNA vaccine coverage on Pharmaceutical Technology (or Clinical Trials Arena) is supported by Trilink. GSK also has an FDA-approved vaccine in the form of Arexvy, though its label only covers those at risk in individuals aged between 50 through 59 years , along with the standard indication of ages 60 and over.
Pharmaceutical Technology
JUNE 10, 2025
Disrupting ACIP’s work introduces dangerous uncertainty about which vaccines will continue to be covered and whether families will have to pay out of pocket for routine immunisations,” the non-profit said. Give your business an edge with our leading industry insights. Give your business an edge with our leading industry insights.
Expert insights. Personalized for you.
81 
Let's personalize your content